| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2473741 | Procedia in Vaccinology | 2011 | 6 Pages |
Abstract
Mucosal immunization with the conserved Shigella protein IpaD formulated with the two-component adjuvant IC31® provided protection in the murine lung model. Neither the recombinant IpaD alone nor IC31® with an irrelevant protein antigen was effective. IpaD-specific serum IgG and IgA levels obtained by IC31®-adjuvantation were comparable to those induced by known mucosal adjuvants.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
